Business Wire

Bardstown Bourbon Company and Brindiamo Expand Relationship with First-of-its-kind Barrel Leasing Program

Share

Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, today announced an exclusive relationship to provide a market-leading barrel leasing program for whiskey brand contract distillation customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209024956/en/

null

Bardstown Bourbon Company, the leading custom American whiskey distiller and Brindiamo, the global leader in sourcing bulk whiskey, will launch an exclusive barrel leasing program -- a timely, tailored solution for non-distilling brands. Roughly one-third of the cost of a new fill barrel is tied up in the wood used to make the barrel. This program allows brands to simplify this significant upfront expense into manageable monthly payments, offering customers the flexibility to plan for tomorrow while maintaining the cashflow to support their needs today. (Photo: Business Wire)

As the whiskey market continues to evolve, this financing program offers a timely, tailored solution for non-distilling brands. Roughly one-third of the cost of a new fill barrel is tied up in the wood used to make the barrel. This program allows brands to simplify this significant upfront expense into manageable monthly payments, offering customers the flexibility to plan for tomorrow while maintaining the cashflow to support their needs today.

“At Bardstown, we pride ourselves on quality, consistency, customer service and innovation. This program was designed to provide an alternative financing solution to customers looking to acquire the highest quality and most consistent distillate available,” said Mark Erwin, Bardstown Bourbon Company CEO. “We are expanding our relationship with long-term partner Brindiamo to exclusively represent this program to our customers.”

While the program will initially be limited to 25,000 barrels annually, Bardstown and Brindiamo are committed to growing the program to meet customer demand. Both sales teams will market and sell the program with Brindiamo serving as the exclusive manager for this innovative offering.

“Bardstown and Green River have been great partners of ours for years, and we admire their ‘Never Stand Still’ attitude. This program is a natural evolution of our collaboration,” said Jeff Steinberg, CEO of Brindiamo. “In today’s economic climate, we believe that customers will prefer the flexibility of leasing the wood to free up capital for their sales and marketing efforts. We are excited to develop this offering with Bardstown Bourbon.”

“Brindiamo is the perfect partner for this as they have the scale, know-how and capability to build a superlative end-to-end experience for our customers,” said Erwin. “We take great pride in creating unprecedented value for our customers and this innovation directly responds to their needs in the face of the market dynamics impacting many brands.”

For questions or to learn more about the barrel leasing program visit bardstownbourbon.com/contract-distilling.

High res imagery and assets can be found here.

About Bardstown Bourbon Company
Bardstown Bourbon Company is pushing the boundaries of innovation while honoring the traditional art of making great whiskey. With the most modern, technically advanced whiskey distillery, Bardstown Bourbon Co. combines distillation and spirited hospitality into a modern, authentic bourbon experience unlike any other on the Kentucky Bourbon Trail™. Named 2023 Worldwide Whiskey Producer of the Year by IWSC and boasting the highest rated bourbon in the world, Bardstown Bourbon Co. is working to push the entire industry in a direction that is more innovative, more transparent and more collaborative. Bardstown Bourbon Co is a top ten distiller by volume in the U.S. For more information visit BardstownBourbon.com.

About Brindiamo
Brindiamo is a leading partner to the global whiskey industry, offering expertise and tailored solutions to brands, distilleries, and suppliers. Known for its ability to simplify complexity, Brindiamo specializes in barrel and liquid management, financing, logistics, and strategic services that help clients navigate the challenges of whiskey production. As the premier sourcing partner for bulk American, Scotch, Irish, and world whiskies, Brindiamo provides unparalleled access to premium liquid. Brindiamo supports its partners every step of the way, delivering creative solutions and unmatched value from wood to glass.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241209024956/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye